Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 4/20 | 0.30 |
| ▸ | RAB9A | P51151 | 4/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.30 |
| ▸ | HTT | P42858 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15893686 | 1.00 | F2 (0.43) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL446590 | 0.85 | F2 (0.44) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2339827 | 0.82 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2339824 | 0.82 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL17070555 | 0.81 | CA1 (0.37) | CA12CA14CA1CA7CA2 | |
| SCHEMBL2369616 | 0.80 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL2369612 | 0.80 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL16298358 | 0.80 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL14493144 | 0.78 | F2 (0.39) | F2PRSS1PRSS2PRSS3CA12 | |
| SCHEMBL24927874 | 0.75 | F2 (0.36) | F2PRSS1PRSS2PRSS3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786539-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20180177812-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2018-06-28 | — | — | US | disclosed |
| US-20180066008-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-08 | — | — | US | disclosed |
| US-9889182-B2 | Assisted enzyme replacement therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9809621-B2 | Stable peptide-based PACE4 inhibitors | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-9724434-B2 | Lysine oligomer derivative and cartilage tissue marker made thereof | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160137617-A1 | NEW MACROCYCLIC AMIDINOUREA DERIVATIVES, METHODS OF PREPARATION AND USES THEREOF AS CHITINASE INHIBITORS | CYGNET BIOSCIENCES B.V. | 2016-05-19 | — | — | US | disclosed |
| US-9249275-B2 | Polyionic dendrimer and hydrogel comprising same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150376145-A1 | STABLE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140221292-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2014-07-24 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20120196933-A1 | MEXILETINE PRODRUGS | FRANKLIN RICHARD (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101041-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120077863-A1 | GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS | UCL BUSINESS PLC (GB) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180066008-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | FUT6, MGAM, B3GNT2 | F2 4827/4885PRSS1 565/4885PRSS2 682/4885 |
| US-20180177812-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, UGGT1, ARSA | F2 4145/4885PRSS1 1427/4885PRSS2 1392/4885 |
| US-20160137617-A1 | NEW MACROCYCLIC AMIDINOUREA DERIVATIVES, METHODS OF PREPARATION AND USES THEREOF AS CHITINASE INHIBITORS | CHIT1, CHIA, ENGASE | F2 828/4885PRSS1 426/4885PRSS2 365/4885 |
| US-11786539-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, UGGT1, ARSA | F2 4145/4885PRSS1 1427/4885PRSS2 1392/4885 |
| US-20120196933-A1 | MEXILETINE PRODRUGS | SLC16A1, MTPN, SLC16A3 | F2 4772/4885PRSS1 1325/4885PRSS2 2689/4885 |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | F2 3237/4885PRSS1 1865/4885PRSS2 2260/4885 |
| US-20140221292-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | CD44, PCNA, GMNN | F2 3709/4885PRSS1 4742/4885PRSS2 4183/4885 |
| US-20120189601-A1 | ASSISTED ENZYME REPLACEMENT THERAPY | GAA, GLA, ENPEP | F2 1506/4885PRSS1 221/4885PRSS2 192/4885 |
| US-20120101041-A1 | POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME | CD44, PCNA, GMNN | F2 3709/4885PRSS1 4742/4885PRSS2 4183/4885 |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | FURIN, DNPEP, PRAP1 | F2 4100/4885PRSS1 100/4885PRSS2 261/4885 |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | BTD, HLCS, BRD4 | F2 23/4885PRSS1 1991/4885PRSS2 2024/4885 |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, KCNH1 | F2 4510/4885PRSS1 1437/4885PRSS2 1692/4885 |
| US-20150376145-A1 | STABLE SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, CACNA1B | F2 3214/4885PRSS1 2178/4885PRSS2 2339/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | F2 4085/4885PRSS1 1506/4885PRSS2 1875/4885 |
| US-20120077863-A1 | GUANIDINO-SUBSTITUTED BI-AND POLYPHENYLS AS SMALL MOLECULE CARRIERS | CFTR, GNB1, GMPS | F2 794/4885PRSS1 1267/4885PRSS2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.